SELLAS Life Sciences

Sellas Life Sciences raised about $28.7 million in April and May from the exercise of warrants on common stock, bolstering its balance sheet and increasing liquidity. The stock is trading near its 52-week high and the market capitalization is about $1.69 billion. In the first quarter the company beat expectations with an adjusted loss of $0.05 per share, and the phase‑3 REGAL study of Galinpepimut‑S is approaching the predefined 80th event for the final analysis. » Więcej na de.investing.com

Shares of Sellas Life Sciences climbed to $6.74 and are currently trading just below at $6.57 after rising 332% over the past year and 357% in the last six months. A high beta of 2.24 indicates significant volatility; InvestingPro points to a possible fair-value overhang. Market capitalization is around $1.2 billion, and analysts see price targets up to $10. Sellas reported an adjusted Q1 result that beat expectations (loss per share $0.05) and progress in the regulatory Phase 3 study REGAL (78 of 80 events reached, study remains blinded). » Więcej na de.investing.com

SELLAS Life Sciences said its Phase 3 REGAL trial in acute myeloid leukemia reached 78 of a pre-specified 80 events and will begin database lock and blinded review once the 80th event occurs, triggering topline disclosure. The company also launched an 80-patient Phase 2 study of SLS009 in newly diagnosed AML patients unlikely to benefit from standard therapy, with topline data expected in Q4 2026, and reported preclinical data showing SLS009 activity in high-risk AML subtypes. Financially, Q1 R&D and G&A expenses rose, net loss widened to $8.4 million, cash and equivalents were $107.1 million, and the company received an additional $7.5 million post-quarter from warrant exercises. » Więcej na finance.yahoo.com